An open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumors

被引：8
|
作者：
Rodon, J. [1 ]
Li, J. [2 ]
Xue, J. [2 ]
Diao, Y. [3 ]
Xu, Y. [3 ]
Liu, G. [3 ]
Rao, C. [3 ]
Fan, B. [3 ]
Cheng, Y. [3 ]
Wang, J. [3 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Early Drug Dev, Houston, TX 77030 USA
[2] Shanghai East Hosp, Oncol Dept, Shanghai, Peoples R China
[3] Sichuan Kelun Biotech Biopharmaceut Co Ltd, Clin Res Ctr, Chengdu, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
514O
引用
收藏
页码：S585 / S585
页数：1
相关论文
共 50 条
  • [21] Phase I, open-label, first-in-human (FIH) study of JZP815 in advanced or metastatic solid tumors harboring mitogen-activated protein kinase (MAPK) alterations
    Naqash, A-R.
    Wang, J. S.
    Perez, C. A.
    Henry, J. T.
    Bashir, B.
    Panneerselvam, A.
    Markova, S.
    Cheung, R. S.
    Spigel, D. R.
    ANNALS OF ONCOLOGY, 2023, 34 : S496 - S497
  • [22] A first-in-human phase 1 study of the safety and pharmacokinetics of XB002 in patients with inoperable locally advanced or metastatic solid tumors.
    Johnson, Melissa
    Ulahannan, Susanna
    Vandross, Andrae
    Park, Haeseong
    Faoro, Leo
    Faggioni, Raffaella
    Li, Jing
    Chang, Yu-Lin
    Uttamsingh, Shailaja
    Tolcher, Anthony
    CANCER RESEARCH, 2022, 82 (12)
  • [23] Phase 1 first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumors.
    Powderly, John
    Shimizu, Toshio
    LoRusso, Patricia
    Razak, Albiruni
    Miller, Kathy
    Balar, Arjun
    Bruix, Jordi
    Michel, Loren
    Blaney, Martha
    Guan, Xiaowen
    Lacy, Susan
    Lally, Satwant
    Lambert, Stacie
    Leibman, Rachel
    Vosganian, Gregory
    Golan, Talia
    Tolcher, Anthony
    CANCER RESEARCH, 2021, 81 (13)
  • [24] An open-label, multicenter, phase I study of ATG-022 in patients with advanced/metastatic solid tumors (CLINCH).
    Bishnoi, Sarwan
    Cao, Dan
    Mendis, Shehara Ramyalini
    Coward, Jim
    Zhao, Jun
    Xie, Hui
    Zheng, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Phase 1, open-label, first-in-human study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients (pts) with advanced solid tumors
    Shaheen, Montasser
    Markman, Ben
    Carducci, Michael
    Hurvitz, Sara
    Mahadevan, Daruka
    Kotasek, Dusan
    Goodman, Oscar
    Gamelin, Erick
    Chow, Vincent
    Juan, Gloria
    Rasmussen, Erik
    Friberg, Gregory R.
    Vogl, Florian D.
    Desai, Jayesh
    CANCER RESEARCH, 2016, 76
  • [26] A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors
    Rodon, Jordi
    Tawbi, Hussein A.
    Thomas, Anne L.
    Stoller, Ronald G.
    Turtschi, Christian P.
    Baselga, Jose
    Sarantopoulos, John
    Mahalingam, Devalingam
    Shou, Yaping
    Moles, Melissa A.
    Yang, Lin
    Granvil, Camille
    Hurh, Eunju
    Rose, Kristine L.
    Amakye, Dereck D.
    Dummer, Reinhard
    Mita, Alain C.
    CLINICAL CANCER RESEARCH, 2014, 20 (07) : 1900 - 1909
  • [27] First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT901 as monotherapy in patients with select advanced solid tumors
    Harvey, R. Donald
    Falchook, Gerald Steven
    Naqash, Abdul Rafeh
    Kim, Joseph W.
    Dowlati, Afshin
    Le Bruchec, Yvan
    Coudert, Isabelle
    Ervin-Haynes, Annette L.
    Sommerhalder, David
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
    Mettu, Niharika B.
    Ulahannan, Susanna, V
    Bendell, Johanna C.
    Garrido-Laguna, Ignacio
    Strickler, John H.
    Moore, Kathleen N.
    Stagg, Robert
    Kapoun, Ann M.
    Faoro, Leonardo
    Sharma, Sunil
    CLINICAL CANCER RESEARCH, 2022, 28 (05) : 882 - 892
  • [29] A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR 3 CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors
    Weickhardt, A. J.
    Frentzas, S.
    Lemech, C.
    Srimani, J.
    Yin, J.
    Trepicchio, W. L.
    Gorgun, C.
    Kichenadasse, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S492 - S492
  • [30] A phase Ia/Ib, open-label first-in-human study of the safety, tolerability, and feasibility of gene-edited autologous NeoTCR-T cells (NeoTCR-P1) administered to patients with locally advanced or metastatic solid tumors.
    Chmielowski, Bartosz
    Ejadi, Samuel
    Funke, Roel
    Stalligs-Schmitt, Todd
    Denker, Mitch
    Frohlich, Mark Walter
    Franzusoff, Alexis J.
    Abedi, Mehrdad
    Cristea, Mihaela C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345